Xencor (XNCR) reported a Q4 net loss of $0.62 per diluted share, wider than its loss of $0.43 year earlier.
Analysts surveyed by FactSet expected a loss of $0.78.
Revenue for the quarter ended Dec. 31 was $52.8 million, compared with $51 million a year earlier.
Analysts surveyed by FactSet expected $20.4 million.
The clinical-stage biopharmaceutical company said it expects to end 2025 with cash, cash equivalents and marketable debt securities in a range of $535 million to $585 million, and to have cash to fund research, development programs and operations into 2028.
Price: 14.81, Change: +0.43, Percent Change: +2.99
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。